{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:58:03Z","timestamp":1780732683841,"version":"3.54.1"},"reference-count":33,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the efficacy and safety of 0.01% atropine eye-drops in controlling myopia progression over 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Experimental, analytical, prospective, randomised and longitudinal study, in 361 right eyes from 361 children randomised into the control group (177 eyes without treatment) and treatment group (184 eyes with 0.01% atropine eye-drops). Children assigned to the treatment group used 0.01% atropine once a day every night and the control group\u2019s children did not use any treatment or placebo. All the subjects completed an eye examination every 6 months for the 5 years of follow-up. The examination included subjective and objective refraction with cycloplegia, axial length (AL), keratometry and anterior chamber depth (ACD) to evaluate the efficacy of the treatment. It also included the anterior and posterior pole examination to evaluate the safety of the treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The SE increased \u22120.63\u00b10.42D in children after 5 years of treatment with 0.01% atropine, while in the control group the increase was \u22120.92\u00b10.56D. AL increased 0.26\u00b10.28\u2009mm in the treatment group compared with 0.49\u00b10.34\u2009mm in the control group. Atropine 0.01% showed an efficacy of 31.5% and 46.9% in the control of the SE and AL increase, respectively. ACD and keratometry did not have significant changes between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Atropine 0.01% is effective in slowing myopia progression in a European population. There were no side effects after 5 years of 0.01% atropine.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2022-322808","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:20:16Z","timestamp":1685726416000},"page":"715-719","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Five-year results of atropine 0.01% efficacy in the myopia control in a European population"],"prefix":"10.1136","volume":"108","author":[{"given":"Manuel","family":"Moriche-Carretero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remedios","family":"Revilla-Amores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Guti\u00e9rrez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Moreno-Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Martinez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2583-1789","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"S\u00e1nchez-Tena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-4581","authenticated-orcid":false,"given":"Cristina","family":"Alvarez-Peregrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2024082217252057000_108.5.715.1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/OPX.0000000000000980","article-title":"What public policies should be developed to deal with the epidemic of myopia","volume":"93","author":"Morgan","year":"2016","journal-title":"Optom Vis Sci"},{"key":"2024082217252057000_108.5.715.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307724"},{"key":"2024082217252057000_108.5.715.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-015-0010-0"},{"key":"2024082217252057000_108.5.715.4","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.18-25957","article-title":"IMI \u2013 defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies","volume":"60","author":"Flitcroft","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2024082217252057000_108.5.715.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.030"},{"key":"2024082217252057000_108.5.715.6","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2654170","article-title":"Threshold values of myopic Anisometropia causing loss of Stereopsis","volume":"2019","author":"Gaw\u0119cki","year":"2019","journal-title":"J Ophthalmol"},{"key":"2024082217252057000_108.5.715.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.11.010"},{"key":"2024082217252057000_108.5.715.8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biomedicines8040078","article-title":"Atropine differentially modulates ECM production by ocular fibroblasts, and its ocular surface toxicity is blunted by colostrum","volume":"8","author":"Cristaldi","year":"2020","journal-title":"Biomedicines"},{"key":"2024082217252057000_108.5.715.9","doi-asserted-by":"publisher","DOI":"10.1017\/S0952523800171184"},{"key":"2024082217252057000_108.5.715.10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1055\/s-0031-1299240","article-title":"Dopaminrezeptoren des Hornhautepithels und -endothels","volume":"229","author":"Gr\u00fcb","year":"2012","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"2024082217252057000_108.5.715.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2017.6638","article-title":"Low-dose atropine for myopia control: considering all the data","volume":"136","author":"Bullimore","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2024082217252057000_108.5.715.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.062"},{"key":"2024082217252057000_108.5.715.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"2024082217252057000_108.5.715.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.011"},{"key":"2024082217252057000_108.5.715.15","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0043"},{"key":"2024082217252057000_108.5.715.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.031"},{"key":"2024082217252057000_108.5.715.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-020-01746-w","article-title":"Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"2024082217252057000_108.5.715.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.07.004"},{"key":"2024082217252057000_108.5.715.19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"2024082217252057000_108.5.715.20","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050900","article-title":"The role of atropine in preventing myopia progression: an update","volume":"14","author":"Chierigo","year":"2022","journal-title":"Pharmaceutics"},{"key":"2024082217252057000_108.5.715.21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia a meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2024082217252057000_108.5.715.22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch Soc Esp Oftalmol"},{"key":"2024082217252057000_108.5.715.23","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye (Lond)"},{"key":"2024082217252057000_108.5.715.24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jcm10194384","article-title":"Effects of 0.01% atropine instillation assessed using swept-source anterior segment optical coherence tomography","volume":"10","author":"Mitsukawa","year":"2021","journal-title":"J Clin Med"},{"key":"2024082217252057000_108.5.715.25","doi-asserted-by":"crossref","first-page":"5125243","DOI":"10.1155\/2020\/5125243","article-title":"Comparative study of the effects of 1% atropine on the anterior segment","volume":"2020","author":"Zhou","year":"2020","journal-title":"J Ophthalmol"},{"key":"2024082217252057000_108.5.715.26","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1167\/iovs.14-14716","article-title":"Analysis of changes in refraction and biometry of atropine- and placebo-treated eyes","volume":"56","author":"Kumaran","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2024082217252057000_108.5.715.27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5935\/0004-2749.20140059","article-title":"Effects of 1% Cyclopentolate hydrochloride on anterior segment parameters obtained with Pentacam in young adults","volume":"77","author":"Arici","year":"2014","journal-title":"Arq Bras Oftalmol"},{"key":"2024082217252057000_108.5.715.28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/jop.2012.0145","article-title":"Influences of tropicamide on anterior segment parameters with Pentacam in healthy individuals","volume":"29","author":"Palamar","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"2024082217252057000_108.5.715.29","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1111\/j.1755-3768.2011.02122.x","article-title":"Influences of Cyclopentolate hydrochloride on anterior segment parameters with Pentacam in children","volume":"89","author":"Palamar","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"2024082217252057000_108.5.715.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-022-02385-z","article-title":"Effect of 0.02% and 0.01% atropine on Astigmatism: a two-year clinical trial","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"2024082217252057000_108.5.715.31","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.147421"},{"key":"2024082217252057000_108.5.715.32","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0492"},{"key":"2024082217252057000_108.5.715.33","unstructured":"Consejer\u00eda de Presidencia . Comunidad de Madrid, ORDEN 11994\/2012, de 21 de Diciembre, de la Consejer\u00eda de Educaci\u00f3n, Juventud Y Deporte, Por La que se Regula La Jornada Escolar en Los Centros Docentes que Imparten Segundo Ciclo de Educaci\u00f3n Infantil Y Educaci\u00f3n Primaria en La Comunidad de Madrid. Spain, 2013: 71\u20136. Available: https:\/\/www.bocm.es\/"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2022-322808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:28:26Z","timestamp":1724372906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2022-322808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bjo-2022-322808"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2022-322808","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}